This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
A recent data analysis showed that obesity increases the risk of death from estrogen receptor (ER)-positive breast cancer for women who have not been through menopause.
A large, long-term study showed for the first time that women with BRCA1 mutations should undergo preventive surgical removal of the ovaries (prophylactic oophorectomy) by age 35 to achieve the greatest reduction in ovarian cancer risk. Researchers showed that waiting until a later age to have the surgery was associated with a significantly higher ovarian cancer risk. In addition, the investigators reported for the first time that prophylactic oophorectomy reduces the overall risk of death by 77 percent among women with either a BRCA1 or BRCA2 mutation.
Results from a new study show that the medication enzalutamide (Xtandi) lengthens the lives of men with metastatic castration-resistant prostate cancer by almost a third. Metastatic castration-resistant prostate cancer (mCRPC) is cancer that has spread to parts of the body other than the prostate and continues to grow and spread without needing the male sex hormone testosterone. Enzalutamide is a type of hormone therapy called an androgen-receptor blocker or an anti-androgen. For men with prostate cancer, hormone therapy is used to block or lower the levels of hormones called androgens that can be involved in prostate cancer growth.
In a new analysis of cancer clinical trials for adults registered on Clinicaltrials.gov, researchers found that about 20% never finish for reasons unrelated to how well the treatment or procedure being studied works or the side effects it causes. Poor accrual was the most common reason for a clinical trial to not finish. Accrual is the term commonly used to describe the process of placing patients in the clinical trial. Basically, poor accrual means that not enough people volunteered for the clinical trial.
Overall, patients taking ASIs lived about 27 months, compared with 17 months for those who were not taking an ASI. In addition, patients taking ASIs were more likely to have the cancer shrink. Researchers also compared ASIs to other types of medications for high blood pressure, finding that patients taking other types of medications for high blood pressure lived about 18 months. Researchers also found that patients taking a type of cancer treatment known as VEGF therapy had a greater benefit when ASIs were combined with cancer treatment. VEGF therapy, such as sunitinib, sorafenib, axitinib, and bevacizumab also affects the process of angiogenesis, which may mean that an ASI works along with the VEGF therapy to better block the formation of blood vessels that feed cancer growth.
Updated results from a clinical trial conducted in Norway and Sweden show that adding radiation therapy to ongoing oral anti-androgen therapy, a type of hormone therapy, more than halved the rate of deaths from locally advanced prostate cancer, compared to ongoing oral anti-androgen therapy given without radiation therapy. For men with prostate cancer, hormone therapy is used to block or lower the levels of hormones called androgens that can be involved in prostate cancer growth. Locally advanced prostate cancer is when the disease has grown through the capsule, the tissue that covers most of the prostate. When this study first began, surgery was not a standard treatment for this type of prostate cancer, and surgery is still not often used because it can be difficult to remove all of the cancer. Radiation therapy (the use of x-rays to kill cancer cells) is often a good option because it can be directed at tissue beyond the prostate to kill cells outside the capsule.
New results from a large clinical trial show that a drug taken by mouth is just as effective as one given by infusion for people with stage II or stage III rectal cancer. These patients received radiation therapy and chemotherapy with either capecitabine (Xeloda) or 5-fluorouracil (5-FU, Adrucil) before surgery. The researchers also found that adding another drug, oxaliplatin (Eloxatin), did not provide any additional benefits and caused more side effects.
Early results from an ongoing phase II clinical trial have shown that a new chemotherapy combination, CAPTEM, may be an effective second-line treatment option for patients with a neuroendocrine tumor that has spread to other parts of the body, even for tumors that haven’t responded to other standard (commonly used) treatments. A second-line treatment is given if the first treatment does not work, starts but then stops working, or causes serious side effects. CAPTEM combines two drugs, capecitabine (Xeloda) and temozolomide (Temodar), which are given in a specific order—capecitabine first, temozolomide second—based on research that showed this might be more effective than giving both drugs at the same time.
Researchers have found that treatment with two different vaccines, GVAX Pancreas followed by CRS-207, helps people with metastatic pancreatic ductal adenocarcinoma (PDAC) live longer. PDAC is the most common type of pancreatic cancer. This study shows that immunotherapy (treatment designed to boost the body's natural defenses to fight the cancer) can help treat pancreatic cancer and appears to cause less serious side effects than chemotherapy.
Combining the chemotherapy drug paclitaxel (Taxol) with a monoclonal antibody known as ramucirumab helps people with stomach or gastroesophageal junction (GEJ, lower part of the esophagus that connects to the stomach) cancer that has spread to other parts of the body live longer than paclitaxel treatment alone, according to a new study. These treatments were given as second-line therapy (treatment given if the first does not work, starts but then stops working, or causes serious side effects). The researchers also noted that people who received the drug combination reported a better quality of life.